Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...

The system is compatible with 1.5T and 3T magnetic resonance imaging scans and eliminates the need for an implanted battery.

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test. Mont-Saint-Guibert, Belgium– August 2, 2022, 8:00am CET/ 2:00am ET– Nyxoah SA, a ...

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business UpdatesAnnounced on August 8, 2025, that the U.S.

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Nyxoah NYXH is gearing up to announce its quarterly earnings on Wednesday, 2025-05-14. Here's a quick overview of what investors should know before the release. Analysts are estimating that Nyxoah ...

Nyxoah said the FDA approved the company's Genio system for a subset of patients with moderate to severe obstructive sleep apnea. The system includes a wearable component, which provides patients with ...

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Monday, March 17, 2025, at 8:40am ET. A webcast of the presentation will be available in the Events ...

Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million.